Comparative Analysis of Analytical Techniques for Quantification of Valsartan and Sacubitril in Pharmaceutical Preparations – A Review

Comparative Analysis of Analytical Techniques for Quantification of Valsartan and Sacubitril in Pharmaceutical Preparations – A Review Madhav. B Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Science, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamilnadu, India. R. Gandhimathi* Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Science, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamilnadu, India. https://orcid.org/0000-0002-0595-8766

Accurate measurement of Valsartan and Sacubitril in pharmaceutical formulations is crucial for ensuring both therapeutic efficacy and safety in heart failure treatment. This review compares three analytical techniques—Reverse Phase High-Performance Liquid Chromatography (RP-HPLC), UV spectrophotometry, and LC-MS/MS—aiming to identify the most effective method for drug quantification. RP-HPLC emerges as the most suitable method for routine analysis due to its superior resolution, precision, and reproducibility. In contrast, UV spectrophotometry serves as a simpler, cost-effective solution for bulk drug testing in large batches, offering reduced complexity but with less sensitivity. Advanced techniques such as LC-MS/MS and spectrofluorimetric analysis deliver exceptional sensitivity, making them ideal for pharmacokinetic studies; however, they are less practical for everyday testing. Furthermore, green chemistry initiatives are gaining traction as they minimize environmental impact while maintaining high analytical accuracy. Although RP-HPLC remains the preferred method, the evolving landscape of analytical techniques, coupled with sustainable practices, is reshaping the future of pharmaceutical quality control.
8 31 2025 8 31 2025 1294 1304 https://doi.org/10.13003/0pyd3js 2025-8-31 http://creativecommons.org/licenses/by/4.0/ 10.13005/ojc/410426 https://www.orientjchem.org/vol41no4/comparative-analysis-of-analytical-techniques-for-quantification-of-valsartan-and-sacubitril-in-pharmaceutical-preparations-a-review/ https://www.orientjchem.org/vol41no4/comparative-analysis-of-analytical-techniques-for-quantification-of-valsartan-and-sacubitril-in-pharmaceutical-preparations-a-review/ Juilet M. A review on the development of analytical methods by RP-HPLC for sacubitril/valsartan. Neuro Quantology. 2022 Nov;22(16):1579-1585. Abdullah A, Rusli MF. Valsartan: A brief current review. Pharmacophore. 2020;11(2):58-64. Drug Bank. Sacubitril. Available from: https://go.drugbank.com/drugs/DB09292. Accessed February 21, 2021. Drug Bank. Valsartan. Available from: https://go.drugbank.com/drugs/DB00177. Accessed February 21, 2021. 10.5958/0974-360x.2019.00168.9 Trefi S, Bitar Y, Gilard V. Separation and quantification of sacubitril–valsartan combination in tablet by a new ion-pair HPLC. Res J Pharm Tech. 2019;12(3):1017-1022. Uppalapati J, Umadevi P. Stability indicating RP-HPLC method for the simultaneous estimation of Sacubitril and Valsartan in drug product. J Pharm Sci Res. 2018;10(9):2201-2204. 10.1007/s00059-018-4683-5 DeVecchis R, et al. Cognitive performance of patients with chronic heart failure on sacubitril/valsartan: A retrospective cohort study. Herz. 2019;44(6):534–540. 10.1007/s40256-020-00445-7 Galo J, Celli D, Colombo R. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions. PMC. 2021;21(3):267-270. 10.1016/j.cardfail.2018.04.010 Perlman A, et al. Cognition- and dementia-related adverse effects with sacubitril/valsartan: Analysis of the FDA adverse event report system database. J Card Fail. 2018;24(8):533-536. 10.1016/j.jad.2020.03.158 Cacciatore F, et al. Effect of sacubitril/valsartan in reducing depression in patients with advanced heart failure. J Affect Disord. 2020;272:132–137. 10.31525/fda2-ucm635083.htm Gottlieb S. FDA Statement on the FDA’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issues. 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps. Accessed Jan 25, 2019. 10.20959/wjpps20174-8965 Merguraja N, Vijayakumar G. RP-HPLC method for the simultaneous estimation of sacubitril and valsartan in bulk and tablet dosage form. Int J Res Publ Rev. 2021;2(10):829-840. 10.47760/ijpsm.2022.v07i06.001 Singh C. Sacubitril/valsartan (Entresto): A review on development of analytical methods and its assessment in pure, bulk formulation, biological fluids, and pharmaceutical preparation. 2022;7(6):1-38. 10.1016/j.jchf.2014.09.001 Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670. Fala L. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. Am Health Drug Benefits. 2015;8(6):330-334. 10.1136/heartjnl-2017-311295 Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril/valsartan: Beyond natriuretic peptides. Heart. 2017;103(20):1569-1577. 10.1002/jssc.202200363 Yerra S, et al. Development and validation of a novel stability-indicating reverse phase HPLC method for the determination of sacubitril–valsartan premix stereoisomers: Cellulose tris(4-methylbenzoate) stationary phase. J Sep Sci. 2022;45(19):3714-3724. 10.5958/2231-5659.2018.00003.6 Phalguna, Y., Noor Jahan, N. Indraja, and Satheesh G. Kumar. “Analytical method development and validation for the estimation of sacubitril and valsartan in combined pharmaceutical dosage forms by RP-HPLC.” Asian Journal of Research in Pharmaceutical Science 8, no. 1 (2018): 09-16. 10.1002/bmc.5240 Subramanian, Velusamy B., Naresh Kumar Katari, Vijetha Ponnam, Naresh Konduru, Thirupathi Dongala, Vishnu M. Marisetti, and Govind Vyas. “Stability‐indicating reversed‐phase‐HPLC method development and validation for sacubitril/valsartan complex in the presence of impurities and degradation products: Robustness by quality‐by‐design approach.” Biomedical Chromatography 36, no. 1 (2022): e5240. 10.1039/c8py00966j Peltier, Raoul, Agnieszka Bialek, Agnès Kuroki, Caroline Bray, Liam Martin, and Sébastien Perrier. “Reverse-phase high performance liquid chromatography (RP-HPLC) as a powerful tool to characterise complex water-soluble copolymer architectures.” Polymer Chemistry 9, no. 46 (2018): 5511-5520. 10.47760/ijpsm.2022.v07i06.001 Singh, chandni k. “sacubitril/valsartan (entresto): a review on development of analytical methods and its assessment in pure, bulk formulation, biological fluids and pharmaceutical preparation.” (2022). Kamal, Amira H., Samah F. El-Malla, and Sherin F. Hammad. “A review on UV spectrophotometric methods for simultaneous multicomponent analysis.” Eur J Pharm Med Res 3, no. 2 (2016): 348-60. 10.1016/j.jpba.2023.115829 Yang, Quancheng, Peng Cao, Yi Lv, Hua Peng, and Xuejia Zhai. “Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.” Journal of Pharmaceutical and Biomedical Analysis 238 (2024): 115829. 10.1016/j.saa.2021.119748 Youssef, Rasha M., Sara A. El-Nahass, Sobhi A. Soliman, and Sameh E. Younis. “Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets.” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 256 (2021): 119748. 10.1016/j.teac.2022.e00157 Kaya, S. Irem, Ahmet Cetinkaya, and Sibel A. Ozkan. “Green analytical chemistry approaches on environmental analysis.” Trends in Environmental Analytical Chemistry 33 (2022): e00157. 10.1016/j.microc.2024.110054 Tiris G, Genc AA, Erk N. Simultaneous analysis of sacubitril and valsartan by novel analytical methods with green approach. Microchem J. 2024;199:110054. Yadav P, Mahendrakumar. Study on degradation behaviour and impurity profiling of drugs and their formulation used in the treatment of cardiovascular disorders. Dissertation, Gujarat Technological University, Ahmedabad; 2024. 10.1002/bmc.5550 Cholleti V, et al. Development and validation of a stability-indicating, single HPLC method for sacubitril–valsartan and their stereoisomers and identification of forced degradation products using LC–MS/MS. Biomed Chromatogr. 2023;37(2):e5550. 10.1002/bmc.5240 Subramanian VB, et al. Stability-indicating reversed-phase HPLC method development and validation for sacubitril/valsartan complex in the presence of impurities and degradation products: robustness by quality-by-design approach. Biomed Chromatogr. 2022;36(1):e5240. Sivaram B, Shyam T. Stability-indicating RP-HPLC method development and validation for determination of sacubitril impurities in sacubitril and valsartan microsphere dosage form. [No journal name given]. Kumar TH, et al. Quantification of sacubitril and valsartan in tablet formulation by RP-HPLC method. Int J 1. 2021;10-16. 10.1016/j.saa.2021.119748 Youssef RM, El-Nahass SA, Soliman SA, Younis SE. Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets. Spectrochim Acta A Mol Biomol Spectrosc. 2021;256:119748. 10.1093/chromsci/bmaa054 Bommi S, Sivaganesh S, et al. Quality by design approach to develop stability-indicating method to quantify related substances and degradation products of sacubitril by high-performance liquid chromatography. J Chromatogr Sci. 2020;58(9):844-858. 10.7324/japs.2020.102015 Prajapati P, Bhayani D, Mehta P. Development and validation of a stability indicating UHPLC method for Sacubitril/Valsartan complex in the presence of impurities and degradation products. J Appl Pharm Sci. 2020;10(2):097-107. 10.5958/0974-4150.2019.00002.6 Madhuri P, Kumar HT, Rao YS, Prasada Rao KV. UV spectrophotometric method for estimation of sacubitril in synthetic mixture. Asian J Res Chem. 2019;12(1):7-10. 10.1007/164_2016_77 Khder, Yasser, Victor Shi, John JV McMurray, and Martin P. Lefkowitz. “Sacubitril/valsartan (LCZ696) in heart failure.” Heart Failure (2017): 133-165.Zhou L, et al. A liquid chromatographic method for separation of sacubitril–valsartan and their stereoisomeric impurities. Anal Methods. 2018;10(9):1046-1053. 10.5958/2231-5675.2016.00023.5 Raul, Saroj Kumar, Gopal Krishna Padhy, Pramudula Ramya Krishna, and Boddu Uma Madhu Priya. “UV Spectrophotometric method development and validation for the estimation of valsartan in bulk and pharmaceutical dosage form.” Asian Journal of Pharmaceutical Analysis 6, no. 3 (2016): 147-150. 10.1007/s10337-017-3425-9 Moussa, Bahia A., Hanaa MA Hashem, Marianne A. Mahrouse, and Sally T. Mahmoud. “Experimental design approach in HPLC method development: application for the simultaneous determination of sacubitril and valsartan in presence of their impurities and investigation of degradation kinetics.” Chromatographia 81 (2018): 139-156. 10.1002/9780470608661.ch4 Amoss, Clinton W., and Norbert M. Maier. “Separation of chiral compounds on Polysaccharide columns.” Chiral Separation Methods for Pharmaceutical and Biotechnological Products (2011): 57-130